Question-and-Answer Session
Operator
(Operator instructions) And your first question comes from the line of Richard Smith with JP Morgan. Please proceed.
Richard Smith – JP Morgan
Yes, good morning everyone.
Fuad El-Hibri
Good morning.
Don Elsey
Good morning Rich.
Richard Smith – JP Morgan
Good morning. Just a quick questions; So with respect to – how many doses was delivered to HSS in the first quarter, do you have the number?
Fuad El-Hibri
Sorry, you were breaking up a bit. Could you repeat your question please?
Richard Smith – JP Morgan
How many doses were delivered to HHS in the first quarter?
Fuad El-Hibri
We delivered approximately 1.8 million doses, Richard. Normally, we don't give specific dose information deliveries at HHS but it's in that ballpark.
Richard Smith – JP Morgan
Okay, thank you. And with respect to the acquisition of the rPA102, could you just provide some details of how it compares to the pharmacy (inaudible) rPA vaccine that's in development?
Fuad El-Hibri
Mike, maybe you can kind of address how –?
Mike Langford
Sure. Some of the differences I guess that's maybe why we are more focused are the expression systems that we use. So the expression system for the product we acquired, rPA102, is (inaudible) as we used to produce our current licensed vaccine. We see some of the advantages of that – of the way it expresses the protein. It expresses the full length protein in a soluble form versus the (inaudible) inclusion bodies, which require breaking up of the cell for the purification and resultant truncated protein and we see that as a potentially more effective vaccine in terms of the fact that it has all of the (inaudible). We think that's one of the significant advantages. We also think that VaxGen prior to our acquisition related substantially increased the stability of this product. We know that there are stability issues with rPA in general from our previous work with this. Although I can't speak directly to the pharmacy products, we do believe we probably have a superior product in terms of stability. So we have the expertise for production. We believe the product produced is superior in terms of recombinant products and we believe the stability that we are going to see is going to be superior to other products.
Richard Smith – JP Morgan
With respect to the RFP that is out there for the second generation, are there any attributes that you still need to work on to fulfill that RFP requirement?
- To read the full transcript on Seeking Alpha, click here »
